Screener
Adaptive Biotechnologies ADPT Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206546
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accrued liabilities | 7,465 | 7,700 |
| Accrued compensation and benefits | 6,217 | 16,992 |
| Current portion of operating lease liabilities | 8,513 | 8,920 |
| Current portion of deferred revenue | 49,397 | 45,194 |
| Current portion of revenue interest liability, net | 5,804 | 4,642 |
| Total current liabilities | 87,011 | 89,915 |
| Long-term liabilities | ||
| Operating lease liabilities, less current portion | 69,115 | 70,228 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Adaptive Biotechnologies's deferred revenue?
- Adaptive Biotechnologies (ADPT) reported deferred revenue of $49.4M in Q1 2026.
- How has Adaptive Biotechnologies's deferred revenue changed year-over-year?
- Adaptive Biotechnologies's deferred revenue decreased by 9.9% year-over-year, from $54.81M to $49.4M.
- What is the long-term trend for Adaptive Biotechnologies's deferred revenue?
- Over 5 years (2020 to 2025), Adaptive Biotechnologies's deferred revenue has grown at a -9.2% compound annual growth rate (CAGR), from $73.32M to $45.19M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Adaptive Biotechnologies's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude